Retrophin Inc., of New York, said it submitted a proposal to the board of Clinuvel Pharmaceuticals Ltd., of Melbourne, Australia, to acquire by scheme of arrangement all of the shares of Clinuvel stock that Retrophin does not own for 0.175 Retrophin shares per Clinuvel share, or A$2.17 (US$2.04) per share in cash.